A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
PHASE4CompletedINTERVENTIONAL
Enrollment
99
Participants
Timeline
Start Date
March 31, 2005
Primary Completion Date
July 31, 2007
Study Completion Date
July 31, 2007
Conditions
SchizophreniaPsychotic Disorders
Interventions
DRUG
risperidone
All Listed Sponsors
lead
Janssen Pharmaceutica N.V., Belgium
INDUSTRY
NCT00216632 - A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™) | Biotech Hunter | Biotech Hunter